|
|
Oxycodone |
Systematic (IUPAC) name |
(5R,9R,13S,14S)-4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one |
Identifiers |
CAS number | 76-42-6 |
ATC code | N02AA05 N02AA55 (in combinations) |
PubChem | 5284603 |
DrugBank | DB00497 |
ChemSpider | 4447649 |
Chemical data |
Formula | C18H21Template:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxNTemplate:OrganicBoxO4Template:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
Mol. mass | 315.364 g/mol |
Synonyms | Eukodal, eucodal; dihydrohydroxycodeinone, 7,8-dihydro-14-hydroxycodeinone, 6-deoxy-7,8-dihydro-14-hydroxy-3-O-methyl-6-oxomorphine |
Physical data |
Melt. point | 219 °C (426 °F) |
Solubility in water | HCl: 166 mg/mL (20 °C) |
Pharmacokinetic data |
Bioavailability | By mouth: 60–87% |
Protein binding | 45% |
Metabolism | Liver: mainly CYP3A, and, to a much lesser extent, CYP2D6 (~5%); 95% metabolized (i.e., 5% excreted unchanged) |
Half life | By mouth (IR): 2–3 hrs (same 1/2 for all ROAs) By mouth (CR): 4.5 hrs |
Excretion | Urine (83%) |
Therapeutic considerations |
Pregnancy cat. | C(AU) B(US) |
Legal status | Controlled (S8)(AU) Schedule I(CA) Class A(UK) Schedule II(US) |
Dependence Liability | High |
Routes | By mouth, sublingual, intramuscular, intravenous, intranasal, subcutaneous, transdermal, rectal, epidural |